investigator-initiated trials

9.12.2014 Health Economics and Outcomes Research (HEOR)

Mitigating the Risks of CER Clinical Trials

By Natalie DeMasi, Research Analyst One of the best ways to prove a product’s worth is to quash a competing product in comparative effectiveness research (CER) clinical trials.  Conversely, one of the best ways to harm a product’s market success...
 

2.13.2013 IIT Studies

Oncology IITs – Pair with Research Organizations for Success

In high-pressure therapeutic areas such as oncology, a new model for investigator initiated trials (IITs) is becoming more popular among pharmaceutical companies. Rather than going through an in-house medical grants process to fund IITs, some companies are joining...
 

8.21.2012 IIT Studies

Looking for Better IIT Submissions? Try moving the process online.

As the old saying goes, "Good help is hard to find." Well, sometimes the best option is to make it easier for the help to find you. Our research has shown that Investigator-Initiated Trial proposals are on the rise over the last three years — averaging 173.3...
 

5.9.2012 IIT Studies

Four Guideposts to Improve Investigator-Initiated Trials Payment Processes for FMV Compliance

By David Richardson, Research Team Leader The Office of the Inspector General at Health and Human Services (OIG) has been highly focused recently on tracking and publicizing pharmaceutical companies' payments to thought leader physicians and clinical...
 

3.16.2012 IIT Studies

Investigator Initiated Trial Management Earns the Dedicated Resources It Deserves

By Ryan McGuire, Senior Research Analyst Pharmaceutical companies are growing more strategic in their investigator initiated trial (IIT) selection. As Research and Development organizations have sharpened their focus on mission-critical pre-approval...
 

1.4.2012 Medical Affairs

Investigator Initiated Trial Budgets Set to Rise in 2012

Our current review of pharmaceutical and biotechnology strategy for the new year finds that 42 percent of companies will be increasing their budgets for investigator initiated trials. Companies fund investigator initiate trials (IITs) to support additional clinical...
 

12.6.2011 IIT Studies

Internet-Based Investigator Initiated Trial Submission Systems Grow

Over Half of Drug Companies Now Use Electronic or Web-Based Tools for Managing Proposals Electronic or web-based submission systems for investigator initiated trial (IIT) proposals are now in place at 58% of biopharmaceutical companies, and that number is expected...
 

11.29.2011 IIT Studies

83% of Investigator Initiated Trials Lead to Medical Publications

While sponsors maintain editorial distance from investigators' findings, they increasingly push researchers to take action on publication Published data from investigator-initiated trials (IIT) have proven extremely valuable for both scientific and commercial...
 

9.20.2011 IIT Studies

Investigator Initiated Trials Increasingly Impacted by FMV Concerns

Investigator initiated trial (IIT) management teams must incorporate fair-market value (FMV) into their payment protocols to appropriately respond to regulatory scrutiny and maintain compliance. In our new study, "Investigator Initiated Trial Management," 23 percent...
 

9.13.2011 IIT Studies

Investigator Initiated Trial Budgets up 21%, Finds New Study

Blockbuster brands' IIT spending booms with large companies topping $20 million Pharmaceutical and biotech companies increased their investigator initiated trial (IIT) budgets by an average 21 percent this year, and they're not stopping there. Our newest study,...